Norwood to list on AIM

Norwood Immunology (Melbourne, Australia) plans to raise up to L15 million ($27 million) through a June IPO on London's AIM market. The deal would give the company a market cap of about L115 million ($209 million). In the second half, the company expects to begin a Phase II cancer study of Lupron Depot, a GnRH analog from TAP Pharmaceutical Products (Lake Forest, Ill.). ...